Form 8-K - Current report:
SEC Accession No. 0000950170-23-041322
Filing Date
2023-08-10
Accepted
2023-08-10 16:10:30
Documents
14
Period of Report
2023-08-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K elvn-20230810.htm   iXBRL 8-K 57283
2 EX-99.1 elvn-ex99_1.htm EX-99.1 217940
3 GRAPHIC img107523686_0.jpg GRAPHIC 37083
  Complete submission text file 0000950170-23-041322.txt   458313

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT elvn-20230810_pre.xml EX-101.PRE 10309
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT elvn-20230810.xsd EX-101.SCH 2502
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT elvn-20230810_lab.xml EX-101.LAB 14018
8 EXTRACTED XBRL INSTANCE DOCUMENT elvn-20230810_htm.xml XML 4931
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 231159436
SIC: 2834 Pharmaceutical Preparations